Sr. Director, Antibody Drug Conjugates, Discovery & Development

Company: Exelixis
Location: Alameda
Posted on: September 16, 2020

Job Description:

Position Description:

As a member of the biotherapeutics group, the incumbent plays a key role in leading the efforts for advancing the discovery and development of antibody drug conjugates (ADCs) at Exelixis. The incumbent will lead efforts in discovery research and early process development activities of ongoing and new ADC projects.

Position Requirements:

ESSENTIAL DUTIES AND RESPONSIBILITIES:

• Provides ADC expertise in state-of-the-art ADC technologies including linkers, payloads, novel conjugation methods, analytical assessments and testing and bring novel ideas to POC.

• Primary liaison and technical expert from biotherapeutics on ADC related collaborations and internal projects. Manages collaboration work.

• Interacts and collaborates with internal departments and external colleagues to discuss and resolve project needs and issues in research and early development of ADCs

• Provides support in evaluation of ADC research platforms and preclinical licensing candidates as needed.

• Delivers scientific presentations to senior management and external collaborators.

• Follows company intellectual property and compliance policies and practices.

• Complies with company health and safety policies and general laboratory practices.

• May have responsibility for planning and implementing budget.

• Departmental activities such as budget planning, administrative management and employee performance, employee development and planning if position oversees internal employees.

SUPERVISORY RESPONSIBILITIES:

• May directly supervise employee(s).

EDUCATION/EXPERIENCE/SKILLS:

Education:

• Doctoral degree (Ph.D.) in related scientific discipline such as chemistry or biochemistry and a minimum of ten years of experience in the biotechnology/pharmaceutical industry post Ph.D.

Experience:

• Strong background in ADC domain.

• Development of ADC therapeutics from screening to development candidate nomination using different technologies and platforms

• Hands on laboratory experience in ADC discovery including critical reagent generation, identification and optimization of ADCs, protein production, purification, analytics and characterization

• Experience with CDMOs for generation of ADCs for Phase 1 Clinical Trials

• Experience writing intellectual property filings, technical reports and non-clinical IND sections

Knowledge/Skills/Abilities:

• Knowledge of state of the art in different aspects of ADC research including conjugation technologies, linkers and payloads

• Extensive knowledge of ADC platforms, applications and development. Comprehensive understanding of current approaches and emerging technologies in ADCs.

• Knowledge of intellectual property matters, and issues related to ADCs

• Knowledge in oncology therapeutics

• The knowledge to apply advanced scientific and technical principles, theories and concepts, and contribute to the development of new principles and concepts.

• The knowledge to set goals with an understanding of priority and impact to program, department and organization.

JOB COMPLEXITY:

• Works on extremely complex problems where analysis of situations or data requires an evaluation of intangible variables.

• Exercises independent judgment in developing methods, techniques and evaluation criteria for obtaining results.

• Uses professional concepts to contribute to development of company’s concepts and principles and to achieve objectives in creative and effective ways.

DISCLAIMER

The preceding job description has been designed to indicate the general nature and level of work performed by employees within this classification. It is not designed to contain or be interpreted as a comprehensive inventory of all duties, responsibilities and qualifications required of employees assigned to the job.

We are an Equal Opportunity Employer and do not discriminate against any employee or applicant for employment because of race, color, sex, age, national origin, religion, sexual orientation, gender identity, status as a veteran, and basis of disability or any other federal, state or local protected class.

We’ll share your profile. The job poster may use it for jobs with other companies. Learn More

ATTN Investors: $ EXEL will present at three virtual conferences in September. Read our latest press release for more details: https:// bit.ly/3m4z9C4

We're partnering with NBE-Therapeutics on novel antibody-drug conjugates as we continue to build out the Exelixis pipeline. Read more about this deal, our fourth biologics-focused agreement since 2018, here: https:// bit.ly/3idByIg $ EXEL

Men have about a 12% chance of being diagnosed with prostate cancer in their lifetime. This # ProstateCancerAwarenessMonth , learn more about the potential risk factors for this disease.

This use may include analytics, personalization, and ads.

Our team works tirelessly to maintain a high quality of innovative research to maximize the potential impact for cancer patients.

Learn more about joining us in our discovery efforts: https:// bit.ly/3bflOlG .

This use may include analytics, personalization, and ads.

We're committed to fostering a culture that values gender equality. We’re proud that women comprise more than half of our workforce, and hold 44% of our people management and executive leadership roles. # WomensEqualityDay

No matter the role at Exelixis, patients are at the heart of everything we do.

View our current job openings and join us in our mission to help cancer patients recover stronger and live longer https:// bit.ly/2F3qxdU .

This use may include analytics, personalization, and ads.

This National Health Center Week, we recognize community health leaders for their dedication as they work on the frontlines during the COVID-19 pandemic. Thank you for your continued commitment to patient care. # NHCW20

We recognize the value of collaboration within the biotech industry to drive innovation for the patient community and improve cancer care. # WhyWeExel

This use may include analytics, personalization, and ads.

# ESMO20 abstract titles were announced – we look forward to sharing some of the latest data featuring $ EXEL treatments at this year’s virtual meeting.

There are no more Tweets in this timeline.

Keywords: Exelixis, Alameda , Sr. Director, Antibody Drug Conjugates, Discovery & Development, Other , Alameda, California